Proactive – Daniel Tillett on Racura Oncology’s drug advancements

Racura CEO and Managing Director Dr Daniel Tillett speaks with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Dr Tillett discussed the challenges of chemotherapy, including severe side effects, and how Racura Oncology is working to minimise these risks while enhancing treatment effectiveness.